1. Home
  2. EXEL vs WCC Comparison

EXEL vs WCC Comparison

Compare EXEL & WCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXEL
  • WCC
  • Stock Information
  • Founded
  • EXEL 1994
  • WCC 1922
  • Country
  • EXEL United States
  • WCC United States
  • Employees
  • EXEL N/A
  • WCC N/A
  • Industry
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • WCC Telecommunications Equipment
  • Sector
  • EXEL Health Care
  • WCC Consumer Discretionary
  • Exchange
  • EXEL Nasdaq
  • WCC Nasdaq
  • Market Cap
  • EXEL 9.8B
  • WCC 8.1B
  • IPO Year
  • EXEL 2000
  • WCC 1999
  • Fundamental
  • Price
  • EXEL $43.04
  • WCC $167.86
  • Analyst Decision
  • EXEL Buy
  • WCC Buy
  • Analyst Count
  • EXEL 18
  • WCC 8
  • Target Price
  • EXEL $38.76
  • WCC $212.00
  • AVG Volume (30 Days)
  • EXEL 3.9M
  • WCC 635.2K
  • Earning Date
  • EXEL 05-13-2025
  • WCC 05-01-2025
  • Dividend Yield
  • EXEL N/A
  • WCC 1.08%
  • EPS Growth
  • EXEL 237.58
  • WCC 10.34
  • EPS
  • EXEL 2.20
  • WCC 13.26
  • Revenue
  • EXEL $2,298,922,000.00
  • WCC $21,812,500,000.00
  • Revenue This Year
  • EXEL $10.39
  • WCC $4.13
  • Revenue Next Year
  • EXEL $10.74
  • WCC $4.27
  • P/E Ratio
  • EXEL $19.53
  • WCC $12.66
  • Revenue Growth
  • EXEL 24.49
  • WCC N/A
  • 52 Week Low
  • EXEL $20.40
  • WCC $125.21
  • 52 Week High
  • EXEL $48.85
  • WCC $216.17
  • Technical
  • Relative Strength Index (RSI)
  • EXEL 59.93
  • WCC 52.67
  • Support Level
  • EXEL $42.21
  • WCC $161.70
  • Resistance Level
  • EXEL $43.75
  • WCC $175.36
  • Average True Range (ATR)
  • EXEL 1.60
  • WCC 4.00
  • MACD
  • EXEL -0.09
  • WCC -0.29
  • Stochastic Oscillator
  • EXEL 53.96
  • WCC 41.51

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

About WCC WESCO International Inc.

Wesco can be traced back to the late 1800s but was officially founded in 1922, acting as the distribution arm of Westinghouse Electric. Throughout the 1900s, Wesco entered and subsequently exited the consumer electronics, transit, bottling, and nuclear plant distribution markets. It was sold to a private equity firm in 1994 and then went public in 1999, and numerous acquisitions have since been made to fill the gaps in Wesco's geographical and product coverage. Today, the firm primarily distributes electrical, networking, security, and utility equipment used in the construction and repair of structures such as offices, data centers, power transmission lines, and manufacturing plants. Wesco has operations around the globe but generates the majority of its revenue in the United States.

Share on Social Networks: